Sou Hu Cai Jing·2025-08-04 11:17Company Overview - Zhaoyan New Drug Research Center Co., Ltd. focuses on non-clinical safety evaluation services for drugs, preclinical research services, and sales of laboratory animals and related products [1] - The main products include non-clinical research services, clinical services, and experimental model supply [1] Financial Performance - For Q1 2025, the company reported revenue of 287 million yuan, a year-on-year decrease of 11.54% [1] - The net profit for the same period was 41.12 million yuan, showing a year-on-year increase of 115.11% [1] - The gross profit margin was recorded at 28.61% [1] Market Position - As of August 4, the company's stock closed at 31.28 yuan, down 3.04%, with a rolling PE ratio of 60.51 times [1] - The total market capitalization is 23.444 billion yuan [1] - In terms of industry PE ratio, the average for the medical services sector is 47.79 times, with a median of 59.03 times, placing Zhaoyan New Drug at the 30th position [1][2] Institutional Holdings - As of Q1 2025, 17 institutions hold shares in Zhaoyan New Drug, all of which are funds, with a total holding of 10.9687 million shares valued at 231 million yuan [1]